跳至主要内容
临床试验/RBR-479v8tv
RBR-479v8tv招募中3 期

Effect of dose fractionation of Testosterone Cypionete on hematocrit in Transgender Men with Erythrocytosis secondary to testosterone use

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo0 个研究点开始时间: 2022年10月27日最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
0 至 0(—)
性别
Male

入选标准

  • Transgender men with and with a diagnosis of testosterone-induced erythrocytosis will be included.

排除标准

  • Male transgender (MT) with polycythemia vera or secondary to other pathologies (chronic kidney disease, severe lung disease, chronic myeloid leukemia, lymphoma, liver diseases and Cushing's syndrome); MT using hormonal contraceptives or copper IUDs; MT with psychiatric conditions such as severe psychotic disorders, severe personality disorders.

研究者

发起方
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

相似试验